NCT07724457
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 5 more changesShow less
- Start date: Oct 30, 2026 to Jul 27, 2027
- Eligibility criteria expanded, about 516 words
- Study sites: 0 to 1
- Secondary endpoints: details revised at 6 of 6 entries
- Study description expanded, about 1 word
- Notable Start date: Aug 14, 2026 to Oct 30, 2026v3
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
See Detailed Description
See Detailed Description.
Patients receive rituximab IV or rituxan hycela SC on day 1, etoposide IV continuously, doxorubicin IV continuously and vincristine IV continuously on days 1-4, cyclophosphamide IV on day 5, and prednisone PO BID on days 1-5. Patients without baseline CNS disease may also receive methotrexate IT once per cycle for 4-6 treatments. Patients with baseline CNS disease also receive methotrexate IT twice weekly until CSF clears then weekly methotrexate IT for 4 weeks then methotrexate IT once per cycles for remaining cycles. Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET, CT scan, and/or MRI and lumbar puncture with CSF sample collection throughout the study. Patients may undergo bone marrow biopsy and blood sample collection throughout the study.
Patients receive rituximab IV or rituxan hycela SC on day 1, etoposide IV continuously, doxorubicin IV continuously and vincristine IV continuously on days 1-4, cyclophosphamide IV on day 5, and prednisone PO BID on days 1-5. Patients also receive glofitamab IV, over 2-4 hours, on day 6 and 15 of cycle 2, day 6 of cycle 3-5 and days 6, 22 and 43 of cycle 6. Patients without baseline CNS disease may also receive methotrexate IT once per cycle for 4-6 treatments. IT treatment can not be given on the same day as glofitamab. Patients with baseline CNS disease also receive methotrexate IT twice weekly until CSF clears then weekly methotrexate IT for 4 weeks then methotrexate IT once per cycles for remaining cycles. IT treatment can not be given on the same day as glofitamab. Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET, CT scan, and/or MRI and lumbar puncture with CSF sample collection throughout the study.
See Detailed Description
Procedures: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography
Drugs: Carboplatin, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Ifosfamide, Methotrexate, Prednisone, Vincristine
Biologicals: Glofitamab, Obinutuzumab, Rituximab, Rituximab and Hyaluronidase Human
Other: Survey Administration
Sites
1 site in 1 country
- Alliance for Clinical Trials in OncologyChicago, Illinois, United States